Is darolutamide approved for cancers other than prostate cancer?
Darolutamide is an androgen receptor inhibitor approved for the treatment of prostate cancer, based on its established indications. The provided information here does not show approvals for other cancer types.
What are darolutamide’s approved indications?
From the information available, darolutamide’s approvals are tied to prostate-cancer settings (for example, non-metastatic and metastatic hormone-sensitive or castration-resistant disease, depending on country and label language). No additional approved oncology indications for non-prostate cancers are indicated in the provided materials.
Have trials tested darolutamide in other cancers?
Darolutamide has been studied in other disease areas in research settings, but “studied” or “in clinical trials” does not mean it is approved. The question is specifically about approval, and the provided information does not establish approvals for other cancer types.
Can I check approval status by country?
Approval status depends on regulators (FDA, EMA, and others) and local label updates. If you tell me the country/regulator you care about (e.g., U.S. FDA vs. EU/EMA), I can narrow the answer to the exact labeled indications.
Source for patent/market context
For ongoing market and patent context around darolutamide, DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/